Brief: Rallybio Corp Discontinues Rlyb212 Program For Prevention Of Fnait
08/04/2025 14:44
April 8 (Reuters) - Rallybio Corp RLYB.O: RALLYBIO CORP - DISCONTINUES RLYB212 PROGRAM FOR PREVENTION OF FNAIT RALLYBIO CORP: RLYB212 PHASE 2 PK RESULTS DID NOT ACHIEVE TARGET CONCENTRATIONS RALLYBIO CORP - TO INITIATE RLYB116 PK/PD STUDY IN 2Q 2025 Source text: ID:nBw9qT5Wra Further company coverage: RLYB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx